CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04+0.00 (0.00%)
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
CytomX Therapeutics total assets
Total assets on the balance sheet at the end of each period.
CytomX Therapeutics's total assets was $364.68M at Sep 30, 2026. For fiscal 2025 it was $151.57M, up 25.7% from the year before. Over ten years it grew -2.6% a year on average. The highest annual figure on record is $457.11M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.57M | +25.7% |
| FY2024 | Dec 31, 2024 | $120.53M | -40.3% |
| FY2023 | Dec 31, 2023 | $201.79M | -22.7% |
| FY2022 | Dec 31, 2022 | $260.89M | -23.1% |
| FY2021 | Dec 31, 2021 | $339.41M | -5.4% |
| FY2020 | Dec 31, 2020 | $358.66M | +5.1% |
| FY2019 | Dec 31, 2019 | $341.28M | -25.3% |
| FY2018 | Dec 31, 2018 | $457.11M | +15.0% |
| FY2017 | Dec 31, 2017 | $397.64M | +99.7% |
| FY2016 | Dec 31, 2016 | $199.13M | +1.0% |
| FY2015 | Dec 31, 2015 | $197.22M | +169.9% |
| FY2014 | Dec 31, 2014 | $73.06M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $364.68M | +130.4% |
| Q2 FY2026 | Jun 30, 2026 | $381.23M | +117.8% |
| Q1 FY2026 | Mar 31, 2026 | $359.36M | +264.8% |
| Q4 FY2025 | Dec 31, 2025 | $151.57M | +25.7% |
| Q3 FY2025 | Sep 30, 2025 | $158.25M | +13.9% |
| Q2 FY2025 | Jun 30, 2025 | $175.06M | +9.9% |
| Q1 FY2025 | Mar 31, 2025 | $98.50M | -46.7% |
| Q4 FY2024 | Dec 31, 2024 | $120.53M | -40.3% |
| Q3 FY2024 | Sep 30, 2024 | $138.98M | -37.2% |
| Q2 FY2024 | Jun 30, 2024 | $159.22M | -23.9% |
| Q1 FY2024 | Mar 31, 2024 | $184.69M | -21.3% |
| Q4 FY2023 | Dec 31, 2023 | $201.79M | -22.7% |
| Q3 FY2023 | Sep 30, 2023 | $221.17M | -2.4% |
| Q2 FY2023 | Jun 30, 2023 | $209.19M | -19.6% |
| Q1 FY2023 | Mar 31, 2023 | $234.63M | -21.0% |
| Q4 FY2022 | Dec 31, 2022 | $260.89M | -23.1% |
| Q3 FY2022 | Sep 30, 2022 | $226.49M | -39.0% |
| Q2 FY2022 | Jun 30, 2022 | $260.09M | -35.4% |
| Q1 FY2022 | Mar 31, 2022 | $296.83M | -31.6% |
| Q4 FY2021 | Dec 31, 2021 | $339.41M | -5.4% |
| Q3 FY2021 | Sep 30, 2021 | $371.23M | -1.1% |
| Q2 FY2021 | Jun 30, 2021 | $402.44M | -0.0% |
| Q1 FY2021 | Mar 31, 2021 | $434.16M | -0.6% |
| Q4 FY2020 | Dec 31, 2020 | $358.66M | +5.1% |
| Q3 FY2020 | Sep 30, 2020 | $375.18M | +0.7% |
| Q2 FY2020 | Jun 30, 2020 | $402.48M | -0.7% |
| Q1 FY2020 | Mar 31, 2020 | $436.66M | -1.8% |
| Q4 FY2019 | Dec 31, 2019 | $341.28M | -25.3% |
| Q3 FY2019 | Sep 30, 2019 | $372.54M | -22.8% |
| Q2 FY2019 | Jun 30, 2019 | $405.28M | +7.5% |
| Q1 FY2019 | Mar 31, 2019 | $444.51M | +18.1% |
| Q4 FY2018 | Dec 31, 2018 | $457.11M | +15.0% |
| Q3 FY2018 | Sep 30, 2018 | $482.73M | +24.7% |
| Q2 FY2018 | Jun 30, 2018 | $376.94M | +7.1% |
| Q1 FY2018 | Mar 31, 2018 | $376.46M | +111.6% |
| Q4 FY2017 | Dec 31, 2017 | $397.64M | +99.7% |
| Q3 FY2017 | Sep 30, 2017 | $387.04M | – |
| Q2 FY2017 | Jun 30, 2017 | $351.86M | – |
| Q1 FY2017 | Mar 31, 2017 | $177.88M | – |
| Q4 FY2016 | Dec 31, 2016 | $199.13M | – |
See a number that looks wrong?